Cynata Therapeutics Limited · ASX:CYP
Cynata Therapeutics — Shareholder Meeting (November 2022)
20 slides from Cynata Therapeutics's shareholder meeting presentation, Nov 22, 2022
Slide 1: Chairman's 2022 AGM Address
ASX ANNOUNCEMENT 22 November 2022 Chairman’s 2022 AGM Address For personal use only Good morning and welcome to this year’s Annual General Meeting of Cynata Therapeutics Ltd. I am Geoff Brooke, the Non-Executive Chairman, and I am joined today by Dr Ross Macdonald, the Managing Director and Chief Ex
Slide 2: Chairman's 2022 AGM Address (continued)
produce MSC products, eventually at a commercial scale, while allowing Cynata to retain the commercial and developmental rights to our CYP-001 product for acute GvHD. Cynata also received a US$5m payment as part of the new partnership. In light of this, we made the decision to divert resources towar
Slide 3: About Cynata Therapeutics (ASX: CYP)
About Cynata Therapeutics (ASX: CYP) Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenge
Slide 4: A Next Generation Stem Cell Therapeutics Company
For personal use only A Next Generation Stem Cell Therapeutics Company AGM Presentation 22 November 2022 Authorised for release by Dr Ross Macdonald, Managing Director and CEO
Slide 5: Key Highlights: FY22 Clinical & Pre-clinical
Key Highlights: FY22 Clinical & Pre-clinical For personal use only Actively recruiting and Received clearance New phase 1 clinical Actively recruiting and treating patients in the from the FDA for IND trial focused on kidney treating patients in the phase 3 Osteoarthritis application for phase 2 tra
Slide 6: Key Highlights: FY22 Commercial & Corporate
For personal use only Key Highlights: FY22 Commercial & Corporate Signed a Strategic Partnership Dr Jolanta Airey Regained Agreement (SPA) and Strengthened IP appointed as Chief development and Manufacturing Received payment of portfolio, with patents Medical Officer to commercialisation Services Ag
Slide 7: Conventional vs. Cynata's Cymerus MSC manufacturing process
Conventional vs. Cynata’s Cymerus MSC manufacturing process Cells donated Conventional process MSCs For personal use only Cells from Limited quantity Significant MSC 1 multiple donors 2 of MSCs isolated 3 expansion required 4 Cell therapy product Conventional Processes Cells donated Cynata’s patente
Slide 8: Competitive strengths of the Cymerus platform
Competitive strengths of the Cymerus platform Cymerus technology elegantly addresses each of the major challenges faced by existing approaches to manufacturing MSCs, facilitating scalable and reproducible production at low cost For personal use only Conventional manufacture Cymerus platform Mandator
Slide 9: Cynata's technology addresses FDA concerns
Cynata’s technology addresses FDA concerns Cynata’s Cymerus process actively addresses current inefficiencies of MSC manufacturing, de-risking clinical development in the US For personal use only Traditional MSC manufacturing is sub-optimal Cynata’s technology is optimal Other MSC therapy (also targ
Slide 10: Cynata has an advanced and diverse product pipeline
Cynata has an advanced and diverse product pipeline Cynata is targeting attractive market opportunities across a range of indications For personal use only Target area Trial phase Market opportunity Osteoarthritis (OA) Phase 3 underway US$11.6bn2 Diabetic Foot Ulcers (DFU) Phase 1 underway US$9.6bn3
Slide 11: GvHD | Ground-breaking Phase 1 clinical trial results
GvHD | Ground-breaking Phase 1 clinical trial results Cynata’s phase 1 GvHD trial met all safety and efficacy endpoints and broke ground by being the world’s first completed clinical trial of an allogeneic iPSC-derived product For personal use only Key results1 demonstrate safety and efficacy of Cym
Slide 12: aGvHD | Phase 2 clinical trial in aGvHD
aGvHD | Phase 2 clinical trial in aGvHD With a cleared IND from the FDA Cynata expects to commence a clinical trial in acute GvHD by early 2023 For personal use only • Acute Graft vs Host Disease (aGvHD) remains a common complication Key Milestones of allogeneic hematopoietic stem cell transplants (
Slide 13: DFU | Phase 1 clinical trial update
DFU | Phase 1 clinical trial update Enrolment opened in December 2021 with completion expected in 1H23 For personal use only Diabetic Foot • DFU are sores on the feet of patients with diabetes (also known as Key Milestones Ulcers (DFU) diabetic wounds) Sign licence • >400m diabetics globally, with D
Slide 14: Osteoarthritis-SCUlpTOR | Phase 3 clinical trial update
Osteoarthritis-SCUlpTOR1 | Phase 3 clinical trial update Clinical trial underway, sponsored by the University of Sydney and funded by an NHMRC project grant For personal use only • Osteoarthritis (OA) occurs when the cartilage in a joint wears away Key Milestones Osteoarthritis • Causes pain, inflam
Slide 15: Renal | Phase 1 clinical trial update
Renal | Phase 1 clinical trial update Funding to conduct trial secured from Leiden University Medical Center (LUMC) For personal use only • MSCs may reduce or eliminate the requirement for aggressive and toxic Key Milestones Renal anti-rejection drugs, leading to a substantial breakthrough in Transp
Slide 16: Near term catalysts
Near term catalysts Cynata is in a strong position to advance its proprietary Cymerus platform technology For personal use only End 2022 + 1H 2023 ✓ DSMB review in DFU trial ❑ Commence phase 2 trial in aGvHD ❑ Complete recruitment of 30 patients in DFU clinical trial During 2H 2023 ❑ Complete recrui
Slide 17: Board & management
Board & management Highly skilled and experienced senior leadership team with decades of experience For personal use only Dr Geoff Brooke Dr Ross Macdonald Dr Kilian Kelly Chairman Managing Director / CEO Chief Operating Officer • 30+ years experience and a track record of success in • 15+ years exp
Slide 18: Investment Highlights
Investment Highlights Cynata is a clinical stage biotech developing its proprietary CymerusTM platform technology for the scalable manufacture of mesenchymal stem cell (MSC) therapeutic products to treat serious disorders For personal use only Unique Strong safety Multiple Large Significant Manufact
Slide 19: Important information
Important information Summary information ‘propose’, ‘will’, ‘believe’, ‘forecast’, ‘estimate’, ‘target’, ‘outlook’, ‘guidance’, ‘potential’ and other similar This Presentation contains summary information about Cynata Therapeutics Limited and its subsidiaries expressions. The forward looking statem
Slide 20: Contact Us
For personal use only Contact Us Cynata Therapeutics Limited Contact details: Level 3 100 Cubitt Street ross.macdonald@cynata.com Cremorne Victoria 3121 www.cynata.com Australia
Cynata Therapeutics — Shareholder Meeting (November 2022) on 6ix